Abstract
Hydroxyurea is beneficial to patients with sickle cell disease because it increases fetal hemoglobin (HbF), which reduces red blood cell sickling. The mechanism by which hydroxyurea increases fetal hemoglobin is not well established. Martyn et al. show that hydroxyurea treatment of in vitro-differentiated erythroid precursors results in reduced expression of BCL11A and ZBTB7A/LRF, two transcription factors that are well-established repressors of the gamma-globin gene. Interestingly, hydroxyurea also reduces the amount of GATA1 in the cells, and since GATA1 is a positive regulator of the BCL11A and ZBTB7A/LRF genes, this suggests that GATA1 may mediate the effects of hydroxyurea. The work provides hints about the mechanism of action of hydroxyurea, but also leaves open questions about its complex role in increasing fetal hemoglobin.